- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Financial Performance Summary for Torrent Pharmaceuticals Limited**
Torrent Pharmaceuticals reported consolidated revenue of ₹2,809 crores for the quarter, reflecting a 3% year-on-year increase, driven by strong demand in its India segment. Key factors contributing to revenue resilience include robust traction in chronic therapies and effective new launches, despite a temporary setback due to the shutdown of insulin contract manufacturing operations.
Net profit surged 14% YoY to ₹503 crores, aided by a gross margin of 76.0% and operational EBITDA margin of 32.5%. The operational EBITDA for the quarter amounted to ₹914 crores, up 5%, indicating improvement in operational efficiency. However, revenue from Brazil declined by 7%, primarily due to a 17% depreciation of the Brazilian Real, although constant currency revenue demonstrated a 10% growth.
Operational costs rose as R&D expenditure was increased by 19% to ₹151 crores, showcasing Torrent's commitment to innovation. Overall, operational efficiency is reflected in an operating EBITDA margin improvement from 31.1% to 32.2% over the nine-month period.
The balance sheet remains strong, underpinned by a net profit margin improvement to 17.9%. Cash flow indicators reveal solid health, with adequate liquidity to support ongoing strategic initiatives, including the anticipated resumption of insulin production from January 2025.
Given the solid performance trajectory, particularly in the domestic market, and the strategic repositioning to mitigate external pressures, the outlook remains positive. The overall recommendation would be a **hold**, considering both growth prospects and short-term operational challenges.